IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Pfizer Reviews German Investment Over Drug Price Policies

CEO Albert Bourla warned Chancellor Friedrich Merz that government proposals to lower drug prices threaten long-term predictability. The company is now reviewing the timing and scope of its planned investments in Germany following similar pullbacks by Eli Lilly and Boehringer Ingelheim.

Xurve View
Insights:

PFIZER INC is reviewing its planned investments in Germany after government proposals to lower drug prices. This review follows similar investment cuts by ELI LILLY & CO and Boehringer Ingelheim. CEO Albert Bourla warned that the policies threaten the predictability required for long-term pharmaceutical commitments.

Pricing Policies Threaten Capital Expenditure
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.